MaxCyte Receivables

The latest receivables for MXCT is $3.9M as of June 2026. That compares with $5.8M in the prior-year period — down 31.8% year over year. Investors often review this figure alongside MaxCyte's historical trend and sector peers before judging valuation or financial health.

Over the past year, MXCT's receivables moved from $5.8M to $3.9M — a 31.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in MaxCyte's operating scale or balance-sheet position.

A receivables figure of $3.9M for MXCT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MXCT's receivables ($3.9M), review year-over-year change from $5.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack MaxCyte's receivables against similar Materials names. You can also browse sector and industry screens on Stockcircle for a broader set of Materials companies and their key multiples and fundamentals.